Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Active, not recruiting · NCT03380962 · Registry updated 2025-03-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic kidney disease, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-03-24 | NCT03380962 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Stanley Jordan, MD | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Norko Ammerman | Los Angeles | United States | 1 |